Published On: Wed, Oct 19th, 2016

Current Price Targets For Merrimack Pharmaceuticals, Inc. (MACK)


Recently stock market analysts have updated their consensus ratings on shares of Merrimack Pharmaceuticals, Inc. (MACK).

Most recent broker ratings

10/07/2016 – Merrimack Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 7 price target on the stock.

10/04/2016 – Merrimack Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at BTIG Research.

08/08/2016 – Merrimack Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Robert W. Baird. They now have a USD 7 price target on the stock.

08/05/2016 – Merrimack Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Brean Capital. They now have a USD 13 price target on the stock.

08/05/2016 – Merrimack Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at Cowen.

05/20/2016 – Merrimack Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Mizuho. They now have a USD 13 price target on the stock.

12/24/2015 – Merrimack Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 15 price target on the stock.

08/11/2015 – Merrimack Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 16 price target on the stock.

05/13/2015 – Guggenheim began new coverage on Merrimack Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 15 price target on the stock.

11/25/2014 – Merrimack Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at Zacks. They now have a USD 9.9 price target on the stock.

Merrimack Pharmaceuticals, Inc. has a 50 day moving average of 5.24 and a 200 day moving average of 6.03. The stock’s market capitalization is 637.15M, it has a 52-week low of 4.39 and a 52-week high of 10.85.

The share price of the company (MACK) was up +0.61% during the last trading session, with a high of 5.26 and the volume of Merrimack Pharmaceuticals, Inc. shares traded was 2594392.

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).